This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
James Lillie plans to sell up to 18,835 shares of MapLight Therapeutics, Inc. common stock through broker Jefferies LLC. The planned sale has an aggregate market value of $714,034.85, with MapLight reporting 42,620,000 common shares outstanding and an approximate sale date of July 15, 2026.
The shares come from several Restricted Stock Unit grants made between 2023 and 2025. Lillie has also sold MapLight shares over the prior three months, including 24,811 shares for $713,661.87 on May 6, 2026, along with additional smaller transactions in April and May 2026.
MapLight Therapeutics director Troy Cox received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units, each representing one share of voting common stock. These RSUs vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service.
He was also granted a stock option covering 29,804 shares of voting common stock at an exercise price of $28.64 per share, vesting on the same three-year schedule starting June 23, 2027. After these grants, his reported direct holdings include 7,864 shares from RSUs and 29,804 underlying option shares.
MapLight Therapeutics director Babler Martin received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units and a stock option for 29,804 shares of Voting Common Stock at an exercise price of $28.64 per share.
The RSUs and option were granted under the 2025 Equity Incentive Plan and will vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service. Following these grants, Martin holds 7,864 shares of Voting Common Stock directly and the newly granted option covering 29,804 underlying shares.
MapLight Therapeutics director Timothy John Garnett received new equity awards as part of non-employee director compensation. He was granted 3,932 restricted stock units, each representing one share of voting common stock, and a stock option for 14,902 shares at an exercise price of $28.64 per share.
Both the RSUs and the option vest on the earlier of June 23, 2027 or the company’s next annual stockholder meeting, subject to his Continuous Service under the 2025 Equity Incentive Plan. Following these awards, he holds 53,457 shares directly and 14,124 shares indirectly through the Timothy J Garnett Revocable Trust, where he has voting and dispositive power.
MapLight Therapeutics, Inc. reported that director Nanna Liebach Luneborg received new equity awards as part of non-employee director compensation. She was granted 3,932 restricted stock units, each representing one share of voting common stock, and a stock option for 14,902 shares at an exercise price of $28.64 per share.
Both the RSUs and the option were granted under the company’s 2025 Equity Incentive Plan and will vest on the earlier of June 23, 2027, or the date of the next annual stockholder meeting, subject to her continuous service.
MapLight Therapeutics director George Pavlov received new equity compensation. He was granted 3,932 restricted stock units (RSUs), each representing one share of voting common stock, under the company’s 2025 Equity Incentive Plan. After this award, he directly holds 28,932 shares of voting common stock.
He was also granted a stock option covering 14,902 shares of voting common stock at an exercise price of $28.64 per share, expiring on June 22, 2036. Both the RSUs and the option vest on the earlier of June 23, 2027, or the date of MapLight’s next annual stockholder meeting, subject to his Continuous Service under the non-employee director compensation policy.
MapLight Therapeutics director Maria C. Walker received new equity awards as part of non-employee director compensation. She was granted 3,932 restricted stock units, each representing one share of voting common stock. These RSUs vest on the earlier of June 23, 2027 or the company’s next annual stockholder meeting, subject to her continuous service.
Walker also received a stock option for 14,902 shares of voting common stock at an exercise price of $28.64 per share, expiring on June 22, 2036, with the same vesting schedule. After the RSU grant, her direct holdings of voting common stock total 62,703 shares. These are compensation-related awards rather than open-market purchases.
MapLight Therapeutics, Inc. filed an initial insider ownership report naming Troy Cox as a director of the company. The Form 3 data in this excerpt shows no reported purchases, sales, exercises, gifts, or other insider transactions, indicating this is primarily an initial disclosure of his reporting status.
MapLight Therapeutics, Inc. director Babler Martin has filed an initial Form 3, which is the first statement of beneficial ownership for insiders. The structured data shows no reported transactions or derivative positions in this filing, indicating it is a baseline ownership disclosure rather than a trade report.
MapLight Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders. Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares, or approximately 86.56%, were present or represented by proxy, indicating strong participation.
Stockholders elected three directors to serve until the 2029 annual meeting. Martin Babler received 31,424,194 votes for and 3,575,737 withheld, Troy Cox received 34,979,012 votes for and 20,919 withheld, and George Pavlov received 34,220,342 votes for and 779,589 withheld, with 1,883,819 broker non-votes.
Stockholders also ratified the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 36,859,217 votes for, 22,332 against, and 2,201 abstentions.